{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T19:45:00Z","timestamp":1790019900336,"version":"4.0.1"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T00:00:00Z","timestamp":1590192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"public, commercial or not-for-profit sectors"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Juvenile systemic sclerosis (JSSc) with rapidly progressive course is a life-threatening condition associated with a poor prognosis. Recently, rituximab (RTX) has been shown to be a promising treatment for adult patients with SSc. We present a series of four patients with rapidly progressive JSSc successfully treated with RTX.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Clinical, laboratory and functional parameters were collected from four patients with rapidly progressive JSSc treated with RTX for at least 1\u2009year. All patients underwent four yearly courses of i.v. RTX 375\u2009mg\/m2 on day 0 and 14, at 3-month intervals. Low dose oral prednisone and MMF were also administered. Data were recorded at baseline and every 6\u2009months and included pulmonary and myocardial function parameters, muscular, vascular and skin changes. The Juvenile Systemic Sclerosis Severity Score (J4S) estimated the overall disease severity over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Four patients (three males, one female), aged 8\u201317\u2009years, entered the study. Three patients presented with prevalent cardiac involvement, one with severe pulmonary involvement. After 1\u2009year of RTX treatment, all patients showed significant improvement of J4S, Raynaud\u2019s phenomenon and cutaneous involvement. Among those with prevalent cardiac involvement, two showed an improvement of the myocardial function (left ventricular ejection fraction [EF] +37% and +19%, respectively) and in the third arrhythmias disappeared. The patient with severe pulmonary involvement showed a significant improvement of the respiratory function (forced vital capacity +46%, forced expiratory volume in 1\u2009s +33%, diffusing capacity of the lung for carbon monoxide [DLCO] +30%). No major side effects were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our data suggest that a combination of RTX and MMF is effective in arresting the rapid progression of JSSc.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa193","type":"journal-article","created":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T07:07:46Z","timestamp":1586156866000},"page":"3793-3797","source":"Crossref","is-referenced-by-count":21,"title":["Rituximab for rapidly progressive juvenile systemic sclerosis"],"prefix":"10.1093","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2479-3485","authenticated-orcid":false,"given":"Francesco","family":"Zulian","sequence":"first","affiliation":[{"name":"Department of Woman\u2019s and Child\u2019s Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Dal Pozzolo","sequence":"additional","affiliation":[{"name":"Department of Woman\u2019s and Child\u2019s Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Meneghel","sequence":"additional","affiliation":[{"name":"Department of Woman\u2019s and Child\u2019s Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biagio","family":"Castaldi","sequence":"additional","affiliation":[{"name":"Department of Woman\u2019s and Child\u2019s Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renzo","family":"Marcolongo","sequence":"additional","affiliation":[{"name":"Clinical Immunology, Department of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alida Linda Patrizia","family":"Caforio","sequence":"additional","affiliation":[{"name":"Department of Cardiological, Thoracic and Vascular Sciences and Public Health, University of Padua, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Martini","sequence":"additional","affiliation":[{"name":"Department of Woman\u2019s and Child\u2019s Health"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,5,23]]},"reference":[{"key":"2020121319242611200_keaa193-B1","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1002\/art.22207","article-title":"Systemic sclerosis in childhood: clinical and immunologic features of 153 patients in an international database","volume":"54","author":"Martini","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2020121319242611200_keaa193-B2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1517\/21678707.2016.1114454","article-title":"Treatment of rapidly progressive systemic sclerosis: current and future perspectives","volume":"4","author":"Mendoza","year":"2016","journal-title":"Expert Opin Orphan Drugs"},{"key":"2020121319242611200_keaa193-B3","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/rheumatology\/ken388","article-title":"Factors affecting survival in Juvenile Systemic Sclerosis","volume":"48","author":"Martini","year":"2009","journal-title":"Rheumatology (Oxford"},{"key":"2020121319242611200_keaa193-B4","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.3389\/fimmu.2019.01352","article-title":"Immunopathogenesis of juvenile systemic sclerosis","volume":"10","author":"Stevens","year":"2019","journal-title":"Front Immunol"},{"key":"2020121319242611200_keaa193-B5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1346-8138.2009.00763.x","article-title":"B lymphocytes: shedding new light on the pathogenesis of systemic sclerosis","volume":"37","author":"Hasegawa","year":"2010","journal-title":"J Dermatol"},{"key":"2020121319242611200_keaa193-B6","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1002\/art.22847","article-title":"B cell infiltration in systemic sclerosis-associated interstitial lung disease","volume":"56","author":"Lafyatis","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2020121319242611200_keaa193-B7","doi-asserted-by":"crossref","first-page":"954","DOI":"10.2353\/ajpath.2006.060205","article-title":"B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis","volume":"169","author":"Hasegawa","year":"2006","journal-title":"Am J Pathol"},{"key":"2020121319242611200_keaa193-B8","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3109\/03009742.2013.869617","article-title":"Rituximab for systemic sclerosis: arrest of pulmonary disease progression in five cases. Results of a lower dosage and shorter interval regimen","volume":"43","author":"Moazedi-Fuerst","year":"2014","journal-title":"Scand J Rheumatol"},{"key":"2020121319242611200_keaa193-B9","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/rheumatology\/kep093","article-title":"Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study","volume":"49","author":"Daoussis","year":"2010","journal-title":"Rheumatology (Oxford"},{"key":"2020121319242611200_keaa193-B10","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.semarthrit.2016.10.003","article-title":"A multicenter, open-label, comparative study of B-cell depletion therapy with rituximab for systemic sclerosis-associated interstitial lung disease","volume":"46","author":"Daoussis","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"2020121319242611200_keaa193-B11","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1136\/annrheumdis-2013-204522","article-title":"Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group","volume":"74","author":"Jordan","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2020121319242611200_keaa193-B12","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.semarthrit.2014.09.002","article-title":"Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis","volume":"44","author":"Bosello","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"2020121319242611200_keaa193-B13","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1136\/annrheumdis-2018-214816","article-title":"Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study","volume":"78","author":"Elhai","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2020121319242611200_keaa193-B14","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.autrev.2017.12.010","article-title":"Efficacy and safety of rituximab in systemic sclerosis: French retrospective study and literature review","volume":"17","author":"Thiebaut","year":"2018","journal-title":"Autoimmun Rev"},{"key":"2020121319242611200_keaa193-B15","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1093\/rheumatology\/key213","article-title":"Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial","volume":"57","author":"Sircar","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2020121319242611200_keaa193-B16","first-page":"142","article-title":"Combination therapy with rituximab and mycophenolate mofetil in systemic sclerosis. A single-centre case series study","volume":"36(Suppl 113","author":"Fraticelli","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"2020121319242611200_keaa193-B17","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/art.22551","article-title":"The PRES\/ACR\/EULAR provisional classification criteria for juvenile systemic sclerosis","volume":"57","author":"Zulian","year":"2007","journal-title":"Arthritis Care Res"},{"key":"2020121319242611200_keaa193-B18","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1002\/art.34652","article-title":"A preliminary disease severity score for juvenile systemic sclerosis","volume":"64","author":"La Torre","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2020121319242611200_keaa193-B19","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/rheumatology\/keg480","article-title":"Safety and efficacy of iloprost for the treatment of ischaemic digits in paediatric connective tissue diseases","volume":"43","author":"Zulian","year":"2003","journal-title":"Rheumatology (Oxford"},{"key":"2020121319242611200_keaa193-B20"},{"key":"2020121319242611200_keaa193-B21","first-page":"11","article-title":"Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial","volume":"18","author":"Flather","year":"2017","journal-title":"Trials"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/59\/12\/3793\/34890348\/keaa193.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/59\/12\/3793\/34890348\/keaa193.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,13]],"date-time":"2020-12-13T19:25:11Z","timestamp":1607887511000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/59\/12\/3793\/5842179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,23]]},"references-count":21,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,5,23]]},"published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa193","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12]]},"published":{"date-parts":[[2020,5,23]]}}}